Novartis, Sandoz In Tangle With Trade Channels Over Direct Drug Sales In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - A five year-long dispute over drug sales with India's largest trade body - the Pharmaceutical Wholesalers Association - has returned to hound Novartis. The powerful trade association has boycotted all products of Novartis and its generic drugs arm Sandoz in Mumbai, alleging that the two companies have been selling some high-value drugs directly to patients, thereby violating agreements over trade margins and also circumventing laws governing price control of drugs in India
You may also be interested in...
Novartis Wants Tighter Grip Over Its Indian Ops; Announces Open Offer To Up Stake To 90%
MUMBAI - Swiss-headquartered Novartis announced a tender offer to buy an additional stake of up to 39 percent in its majority-owned Indian subsidiary Novartis India. The Swiss drug maker, which markets popular pain killer Voveran (diclofenac) in India among several other products, would raise its stake in the subsidiary to nearly 90 percent if the open offer for the shares passes successfully
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).